EHS
EHS

FDA Approves Fulphila, First Biosimilar to Neulasta

Mylan’s Fulphila is the first biosimilar to Neulasta to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer.
EHS
Back to top button